A recent study carried out by a Japanese research team and published in the International Journal of Clinical Oncology has shown that an alternative “weekday-on and weekend-off regimen” of sunitinib administration for metastatic renal cell carcinoma (RCC) may improve relative dose intensity compared with the conventional 4 weeks on sunitinib, 2 weeks off schedule. The study also showed no difference in adverse event rate or prognoses between the two schedules.
Read more in Renal & Urology News here
